Skip to main content
OnKure Therapeutics, Inc. logo

OnKure Therapeutics, Inc. — Investor Relations & Filings

Ticker · OKUR ISIN · US75974E1038 US Manufacturing
Open in API
Filings indexed 342 across all filing types
Latest filing 2024-06-20 M&A Activity
Country US United States of America
Listing US OKUR

About OnKure Therapeutics, Inc.

https://onkuretherapeutics.com/

OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines for cancer patients. The company is building a pipeline of potentially best-in-class, tumor-agnostic therapies that target biologically validated drivers of cancers, particularly those underserved by current treatments. Its research and development efforts are centered on novel and potentially less toxic kinase inhibitor drugs and epigenetic therapies.

Recent filings

Filing Released Lang Actions
S-4
M&A Activity Classification · 100% confidence The document is a Form S-4 registration statement filed with the SEC, which is used for securities registration in connection with mergers and acquisitions. It details the merger agreement between Reneo Pharmaceuticals, Inc. and OnKure, Inc., including the terms of the merger, stock exchange ratios, PIPE investments, and conditions for closing. The presence of detailed merger terms, stockholder meeting information, and securities registration indicates this is related to M&A activity. The document is not a proxy statement alone, nor a simple announcement, but a comprehensive filing related to the merger transaction. Therefore, the appropriate classification is 'M&A Activity' (TAR).
2024-06-20 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-05-21 English
Director's Dealing 2024
Director's Dealing
2024-05-16 English
Director's Dealing 2024
Director's Dealing
2024-05-16 English
8-K
M&A Activity Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated May 10, 2024, by Reneo Pharmaceuticals, Inc. It details the entry into a material definitive agreement, specifically a merger agreement with OnKure, Inc. The text extensively describes the terms of the merger, stock exchange ratios, stockholder proposals, and conditions for consummation of the merger. The document is a current report disclosing a significant corporate transaction rather than a full annual or quarterly financial report, earnings release, or proxy statement. It is not a simple announcement or a certification but a detailed disclosure of a merger agreement. According to the filing definitions, announcements and documents related to merger proposals or takeover bids fall under the category 'M&A Activity' (Code: TAR). Therefore, this document should be classified as M&A Activity.
2024-05-13 English
425 Filing
M&A Activity Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated May 10, 2024, by Reneo Pharmaceuticals, Inc. It details the entry into a material definitive agreement, specifically a Merger Agreement between Reneo and OnKure, including terms of the merger, stock exchange ratios, stockholder proposals, and conditions for closing. The content is focused on merger transaction details and related agreements. This type of filing is best classified under M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids. The document is substantive and not merely an announcement or a proxy solicitation, so it is not PSI or RPA. Therefore, the correct classification is TAR with high confidence.
2024-05-13 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.